Close Menu

Pairings: Sep 28, 2011

Premium

Martin Madaus has been named Quanterix's permanent CEO. Madaus, who is chairman of the company, had been serving as interim CEO since May when David Okrongly left the Cambridge, Mass.-based company.

Madaus has served as a director of Quanterix since 2010, and became chairman of the firm last December. Prior to joining Quanterix, he served as president, chairman, and CEO of Millipore before it was acquired by Merck KGaA last year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.

Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.

The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.

In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.

Oct
10
Sponsored by
Roche

This webinar will provide an overview of how a pathology laboratory validated a 77-gene next-generation sequencing-based liquid biopsy assay.

Oct
21
Sponsored by
Agilent

Genomics is a key element in the potential of precision medicine to transform oncology. 

Oct
23
Sponsored by
Swift Biosciences

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries.